In re Pharmaceutical Industry Average Wholesale Price Litigation

MEMORANDUM AND ORDER

SARIS, District Judge.

I. INTRODUCTION

Plaintiffs move for certification of two nationwide classes under the unfair and deceptive trade practice laws of more than thirty states. This phase of a multi-year, multidistrict litigation, which has generated multiple national settlements and a bellwether bench trial, involves claims that pharmaceutical manufacturers AstraZeneca1 and BMS2 *86grossly inflated the prices of branded physician-administered drugs by misstating the Average Wholesale Prices (“AWPs”) of these drugs in industry publications. For AstraZeneca, the drug at issue…